Health Affairs January 5, 2024
Amanda Katchmar, Alan B. Cohen

The emergence of cell and gene therapies (CGTs) has been a source of hope for patients living with once-uncurable diseases. Gene therapy involves the introduction of genetic material, usually in a carrier or vector, to the appropriate cells of the body; the goal is to treat disease by, for example, increasing the production of healthy proteins or decreasing the production of disease-causing proteins. Cell therapy aims to treat a disease through modification of a patient’s own cells or transfer of donor cells, such as immune cells, into a patient.

Unfortunately, these blockbuster therapies often make headlines not because of their innovative technology but because of their high price. For example, Zolgensma, a gene therapy for treating spinal muscular atrophy priced...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Congress / White House, FDA, Govt Agencies, Insurance, Patient / Consumer, Pharma / Biotech, Provider
Deep learning uncovers gene targets and potential drugs to slow brain aging
CZI’s Priscilla Chan on ‘Virtual Cells’ AI Models to Cure Diseases
Common Trends in GLP-1 Use Amid Increased Indications
Ensitrelvir Shows Promise Preventing COVID-19 Post Exposure
Gene Therapy Biotech MeiraGTx Strikes Deal Bringing Generative AI to Pivotal Parkinson’s Trial

Share This Article